Overview

Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults

Status:
Terminated
Trial end date:
2020-01-21
Target enrollment:
Participant gender:
Summary
A Phase 2b Study to Determine the Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults aged 18 years and over. To assess the effect of MVA-NP+M1 on the reduction of laboratory confirmed influenza when given as an adjunct to licensed quadrivalent influenza vaccine (QIV) in adults
Phase:
Phase 2
Details
Lead Sponsor:
Vaccitech (UK) Limited
Vaccitech Limited
Collaborator:
Clinical Network Services (CNS) Pty Ltd
Treatments:
Vaccines